Illumina (ILMN) Stock Analysis: AI Score & Alternative Data
ILMN alt-data: revenue climbing, job postings lagging
Is Illumina a buy right now? The alternative data says hold. This ILMN stock analysis is built on the 25+ alternative data signals AltIndex tracks on Illumina every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 51/100: a Hold. The stock trades at $200.63 with a $29B market cap.
The bullish side of the 90-day ledger: revenue up 9.4% YoY to $1.2B, web traffic up 12.4% to 797K monthly visits, and sentiment up 33.3% to 100/100. The drag: job postings down 22.8% to 149 open roles, and just 34% of employees report a positive business outlook. That tension is what keeps the score mid-range.
ILMN’s broader alt-data profile also covers headcount (10K employees, according to LinkedIn), and X followers (96K). Every signal links to its own page with full history, the ILMN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ILMN is just below.
Illumina AI Stock Analysis
Illumina, Inc. is a global leader in genomics, providing comprehensive solutions for sequencing and array-based technologies. These innovations are paving the way for advancements in personalized medicine and molecular diagnostics. The company operates in a dynamic and competitive market, continually striving for scientific and technological breakthroughs.
Analysis generated August 2, 2026.
Recent Illumina Stock Alerts
|
Illumina | August 19 Price is up by 6.3% in the last 24h. |
|
Illumina | August 11 Business Outlook among employees is up by 3% over the last month. |
|
Illumina | August 8 Insider Alert: Meister Keith A. is selling shares |
|
Illumina | August 6 Price is down by -6.1% in the last 24h. |
Illumina Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 797K | 12.4% | |
| Job Posts | 149 | 22.8% | |
| LinkedIn Employees | 10K | 0.9% | |
| Employee Recommend | 48 | 2.1% | |
| Business Outlook | 34 | 0% | |
| Lobbying Cost | $267K | 0% | |
| Sentiment | 100 | 33.3% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 9 | 57.1% | |
| Stocktwits Mentions | 3 | 57.1% | |
| News Mentions | 2 | 71.4% | |
| Stocktwits Subscribers | 13K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 96K | 0% | |
| Instagram Followers | 16K | 1.9% | |
| Youtube Subscribers | 41K | 1.0% | |
| Facebook Followers | 31K | 0% | |
| Facebook Engagement | 16 | 96.7% |
About Illumina (ILMN)
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
| Price | $200.63 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $29B |
| Year Range | $91 – $205 |
| Dividend Yield | 0% |
| PE Ratio | 35.6 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Illumina News
View more →
Illumina (ILMN) Rose on Strong Clinical MomentumAugust 5 - Yahoo Entertainment |
|
 |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026July 30 - PRNewswire |
 |
Illumina expands Billion Cell Atlas program with new AI drug developersJuly 16 - PRNewswire |
|
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026July 9 - PRNewswire |
 |
Adding Eli Lilly’s R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)June 23 - Biztoc.com |
Illumina Earnings & Financial Performance
View all earnings →Illumina Insider Trading Activity
View all →| Meister Keith A. filed to sell 2,089,425 shares at $0.0. Aug 5 '26 |
| Meister Keith A. filed to sell 2,091,875 shares at $0.0. Aug 5 '26 |
| Meister Keith A. filed to sell 2,103,247 shares at $0.0. Aug 5 '26 |
| Meister Keith A. filed to sell 2,320,445 shares at $0.0. Aug 5 '26 |
| Meister Keith A. filed to sell 2,252,398 shares at $0.0. Aug 5 '26 |
Illumina Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gilbert Cisneros |
Mar 10, 26 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
| Thomas H. Kean |
Apr 21, 25 | Buy | $8K+ |
| Rohit Khanna |
Jun 5, 24 | Buy | $8K+ |
| Rohit Khanna |
Jun 5, 24 | Sell | $8K+ |
Stocks Similar to Illumina
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Alnylam PharmaceuticalsALNY |
$239.30 4.7% | $30B | 66 |
 |
BiogenBIIB |
$219.64 3.3% | $31B | 34 |
 |
IncyteINCY |
$126.74 2.7% | $25B | 53 |
 |
West Pharmaceutical ServicesWST |
$352.84 1.8% | $24B | 67 |
 |
Royalty PharmaRPRX |
$60.93 2.1% | $34B | 55 |
Explore Illumina Data
Frequently Asked Questions: Illumina (ILMN)
Illumina has an AltIndex AI Score of 51/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
51/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Illumina (ILMN) stock is $200.63 with a market cap of $29B.
As of today, Illumina’s PE (Price to Earnings) ratio is 35.6.
View the latest Illumina insider transactions to see recent buying and selling activity by company executives and directors.
Check the Illumina congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ILMN stock price chart above shows Illumina’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Illumina technical analysis for RSI, moving averages, and more.
See the stocks similar to Illumina section on this page for companies in the same industry ranked by market cap and AI Score.
